GB9326253D0
(en)
*
|
1993-12-23 |
1994-02-23 |
Smithkline Beecham Biolog |
Vaccines
|
US5690942A
(en)
*
|
1995-06-02 |
1997-11-25 |
American Home Products Corporation |
Adjuvants for viral vaccines
|
GB9513261D0
(en)
*
|
1995-06-29 |
1995-09-06 |
Smithkline Beecham Biolog |
Vaccines
|
ATE355375T1
(de)
|
1996-01-04 |
2006-03-15 |
Novartis Vaccines & Diagnostic |
Bakterioferritin aus helicobacter pylori
|
GB9616351D0
(en)
*
|
1996-08-02 |
1996-09-11 |
Smithkline Beecham Biolog |
Vaccine composition
|
US7517952B1
(en)
*
|
1997-02-25 |
2009-04-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
US20030185830A1
(en)
*
|
1997-02-25 |
2003-10-02 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
US20060024301A1
(en)
*
|
1997-02-25 |
2006-02-02 |
Corixa Corporation |
Prostate-specific polypeptides and fusion polypeptides thereof
|
GB9706957D0
(en)
|
1997-04-05 |
1997-05-21 |
Smithkline Beecham Plc |
Formulation
|
GB9711990D0
(en)
*
|
1997-06-11 |
1997-08-06 |
Smithkline Beecham Biolog |
Vaccine
|
GB9712347D0
(en)
*
|
1997-06-14 |
1997-08-13 |
Smithkline Beecham Biolog |
Vaccine
|
EP1009429B1
(en)
*
|
1997-08-29 |
2009-07-08 |
Antigenics Inc. |
Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
|
GB9718901D0
(en)
|
1997-09-05 |
1997-11-12 |
Smithkline Beecham Biolog |
Vaccine
|
WO1999011241A1
(en)
*
|
1997-09-05 |
1999-03-11 |
Smithkline Beecham Biologicals S.A. |
Oil in water emulsions containing saponins
|
GB9724531D0
(en)
|
1997-11-19 |
1998-01-21 |
Smithkline Biolog |
Novel compounds
|
US6743427B1
(en)
|
1997-12-02 |
2004-06-01 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
US6923964B1
(en)
|
1997-12-02 |
2005-08-02 |
Neuralab Limited |
Active immunization of AScr for prion disorders
|
US6710226B1
(en)
|
1997-12-02 |
2004-03-23 |
Neuralab Limited |
Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
|
US6787523B1
(en)
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US6750324B1
(en)
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
EP1584685B1
(en)
|
1998-02-05 |
2011-04-13 |
GlaxoSmithKline Biologicals SA |
Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with T-helper epitopes and of compositions for vaccination
|
NZ506602A
(en)
*
|
1998-03-09 |
2003-02-28 |
Smithkline Beecham Biolog S |
Combined vaccine compositions against hepatitis B virus and herpes simplex virus and possibly also epstein bar virus, hepatitis A & C viruses, human papilloma virus, varicella zoster virus, human cytomegalovirus, and toxoplasma gondii
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
GB9806095D0
(en)
*
|
1998-03-20 |
1998-05-20 |
Smithkline Beecham Biolog |
Novel compounds
|
KR100797876B1
(ko)
|
1998-04-07 |
2008-01-24 |
코릭사 코포레이션 |
마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
|
GB9808866D0
(en)
|
1998-04-24 |
1998-06-24 |
Smithkline Beecham Biolog |
Novel compounds
|
JP2002513773A
(ja)
|
1998-05-07 |
2002-05-14 |
コリクサ コーポレイション |
アジュバント組成物及びその使用法
|
US20030147882A1
(en)
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
US6306404B1
(en)
|
1998-07-14 |
2001-10-23 |
American Cyanamid Company |
Adjuvant and vaccine compositions containing monophosphoryl lipid A
|
PL346213A1
(en)
|
1998-08-07 |
2002-01-28 |
Univ Washington |
Immunological herpes simplex virus antigens and methods for use thereof
|
GB9819898D0
(en)
*
|
1998-09-11 |
1998-11-04 |
Smithkline Beecham Plc |
New vaccine and method of use
|
US6692752B1
(en)
|
1999-09-08 |
2004-02-17 |
Smithkline Beecham Biologicals S.A. |
Methods of treating human females susceptible to HSV infection
|
GB9820525D0
(en)
|
1998-09-21 |
1998-11-11 |
Allergy Therapeutics Ltd |
Formulation
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
WO2000023105A2
(en)
|
1998-10-16 |
2000-04-27 |
Smithkline Beecham Biologicals S.A. |
Adjuvant systems and vaccines
|
GB9822714D0
(en)
*
|
1998-10-16 |
1998-12-09 |
Smithkline Beecham Sa |
Vaccines
|
EP1137777B1
(en)
|
1998-12-08 |
2011-10-05 |
GlaxoSmithKline Biologicals s.a. |
Novel compounds derived from neisseria meningitidis
|
JP2002531129A
(ja)
|
1998-12-08 |
2002-09-24 |
コリクサ コーポレイション |
クラミジア感染の処置および診断のための化合物および方法
|
US20020119158A1
(en)
|
1998-12-17 |
2002-08-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6579973B1
(en)
|
1998-12-28 |
2003-06-17 |
Corixa Corporation |
Compositions for the treatment and diagnosis of breast cancer and methods for their use
|
US7198920B1
(en)
|
1999-01-29 |
2007-04-03 |
Corika Corporation |
HER-2/neu fusion proteins
|
ES2347428T3
(es)
*
|
1999-02-01 |
2010-10-29 |
EISAI R&D MANAGEMENT CO., LTD. |
Compuestos coadyuvantes inmunologicos.
|
US20040006242A1
(en)
|
1999-02-01 |
2004-01-08 |
Hawkins Lynn D. |
Immunomodulatory compounds and method of use thereof
|
US7915238B2
(en)
*
|
1999-02-01 |
2011-03-29 |
Eisai R & D Management Co., Ltd. |
Immunomodulatory compounds and methods of use thereof
|
US6551600B2
(en)
|
1999-02-01 |
2003-04-22 |
Eisai Co., Ltd. |
Immunological adjuvant compounds compositions and methods of use thereof
|
US6835721B2
(en)
*
|
1999-02-01 |
2004-12-28 |
Eisai Co., Ltd. |
Immunomodulatory compounds and methods of use thereof
|
GB2348132B
(en)
*
|
1999-03-02 |
2004-08-04 |
Nedaa Abdul-Ghani Nasif |
Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils
|
BR0008917A
(pt)
|
1999-03-11 |
2002-01-15 |
Smithkline Beecham Biolog |
Compostos
|
EP2163628A3
(en)
|
1999-03-12 |
2010-06-02 |
GlaxoSmithKline Biologicals S.A. |
Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
|
GB9909077D0
(en)
|
1999-04-20 |
1999-06-16 |
Smithkline Beecham Biolog |
Novel compositions
|
EP1880735A3
(en)
*
|
1999-03-19 |
2008-03-12 |
GlaxoSmithKline Biologicals S.A. |
Vaccine
|
JP2002539826A
(ja)
*
|
1999-03-26 |
2002-11-26 |
スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム |
新規化合物
|
HUP0200760A2
(en)
|
1999-04-02 |
2002-06-29 |
Corixa Corp |
Compounds and methods for therapy and diagnosis of lung cancer
|
GB9908885D0
(en)
*
|
1999-04-19 |
1999-06-16 |
Smithkline Beecham Biolog |
Vccine
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
AU764969B2
(en)
*
|
1999-04-19 |
2003-09-04 |
Smithkline Beecham Biologicals (Sa) |
Vaccines
|
EP1178825B1
(en)
*
|
1999-05-13 |
2011-07-13 |
Wyeth Holdings Corporation |
Adjuvant combination formulations
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
US6635261B2
(en)
|
1999-07-13 |
2003-10-21 |
Wyeth Holdings Corporation |
Adjuvant and vaccine compositions containing monophosphoryl lipid A
|
GB9918319D0
(en)
|
1999-08-03 |
1999-10-06 |
Smithkline Beecham Biolog |
Vaccine composition
|
GB9921146D0
(en)
*
|
1999-09-07 |
1999-11-10 |
Smithkline Beecham Biolog |
Novel composition
|
GB9921147D0
(en)
*
|
1999-09-07 |
1999-11-10 |
Smithkline Beecham Biolog |
Novel composition
|
GB9923176D0
(en)
|
1999-09-30 |
1999-12-01 |
Smithkline Beecham Biolog |
Novel composition
|
EP1808180A3
(en)
|
1999-10-22 |
2010-12-22 |
Sanofi Pasteur Limited |
Modified GP 100 and uses thereof
|
GB0000891D0
(en)
*
|
2000-01-14 |
2000-03-08 |
Allergy Therapeutics Ltd |
Formulation
|
CA2400842C
(en)
*
|
2000-02-23 |
2013-01-15 |
Smithkline Beecham Biologicals S.A. |
Novel compounds
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
AU5162201A
(en)
*
|
2000-04-13 |
2001-10-30 |
Corixa Corporation |
Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
|
AU2001255596A1
(en)
|
2000-04-21 |
2001-11-07 |
Corixa Corporation |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
US7851212B2
(en)
|
2000-05-10 |
2010-12-14 |
Sanofi Pasteur Limited |
Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
|
AU2001268472A1
(en)
*
|
2000-06-16 |
2002-01-02 |
Smith Kline Beecham Corporation |
Icp27-binding polynucleotides
|
SI1542732T1
(sl)
|
2000-06-20 |
2010-01-29 |
Corixa Corp Csc The United Sta |
Fuzijski proteini Mycobacterium tuberculosis
|
AR029540A1
(es)
|
2000-06-28 |
2003-07-02 |
Corixa Corp |
COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
|
GB0108364D0
(en)
|
2001-04-03 |
2001-05-23 |
Glaxosmithkline Biolog Sa |
Vaccine composition
|
DK1296715T4
(en)
|
2000-06-29 |
2016-03-07 |
Smithkline Beecham Biolog |
Multivalent vaccine composition.
|
WO2002009752A2
(en)
|
2000-07-31 |
2002-02-07 |
Eisai Co., Ltd. |
Immunological adjuvant compounds
|
US7229623B1
(en)
|
2000-08-03 |
2007-06-12 |
Corixa Corporation |
Her-2/neu fusion proteins
|
UA79735C2
(uk)
|
2000-08-10 |
2007-07-25 |
Глаксосмітклайн Байолоджікалз С.А. |
Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
|
GB0022742D0
(en)
|
2000-09-15 |
2000-11-01 |
Smithkline Beecham Biolog |
Vaccine
|
GB0025577D0
(en)
*
|
2000-10-18 |
2000-12-06 |
Smithkline Beecham Biolog |
Vaccine
|
DE60131670T2
(de)
|
2000-10-18 |
2008-10-30 |
Glaxosmithkline Biologicals S.A. |
Impfstoffe gegen Krebskrankheiten
|
EP1201250A1
(en)
*
|
2000-10-25 |
2002-05-02 |
SMITHKLINE BEECHAM BIOLOGICALS s.a. |
Immunogenic compositions comprising liver stage malarial antigens
|
NZ593617A
(en)
|
2000-10-27 |
2012-04-27 |
Novartis Vaccines & Diagnostic |
Nucleic acids and proteins from streptococcus groups A & B
|
AU2002249764A1
(en)
*
|
2000-11-16 |
2003-05-06 |
Aurx, Inc. |
Prevention of recurrent viral disease
|
BRPI0115792B1
(pt)
|
2000-11-29 |
2020-05-05 |
Colorado State Univ |
sistema para separação de espermatozóides congelados/descongelados em populações portadoras de cromossomo-x e portadoras de cromossomo-y
|
EP1415005B1
(en)
|
2000-12-07 |
2012-11-21 |
Novartis Vaccines and Diagnostics, Inc. |
Endogenous retroviruses up-regulated in prostate cancer
|
AU2002343321A1
(en)
*
|
2001-01-26 |
2003-01-21 |
Walter Reed Army Institute Of Research |
Isolation and purification of plasmodium falciparum merozoite protein-142
|
US7306806B2
(en)
|
2001-01-26 |
2007-12-11 |
United States Of America As Represented By The Secretary Of The Army |
Recombinant P. falciparum merozoite protein-142 vaccine
|
GB0103171D0
(en)
|
2001-02-08 |
2001-03-28 |
Smithkline Beecham Biolog |
Vaccine composition
|
EP2269639B1
(en)
|
2001-02-23 |
2018-11-28 |
GlaxoSmithKline Biologicals s.a. |
Influenza vaccine formulations for intradermal delivery
|
US20030031684A1
(en)
|
2001-03-30 |
2003-02-13 |
Corixa Corporation |
Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
|
GB0109297D0
(en)
|
2001-04-12 |
2001-05-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP1515982A4
(en)
|
2001-05-09 |
2005-10-26 |
Corixa Corp |
METHODS AND COMPOSITIONS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
|
US20100221284A1
(en)
|
2001-05-30 |
2010-09-02 |
Saech-Sisches Serumwerk Dresden |
Novel vaccine composition
|
TWI228420B
(en)
|
2001-05-30 |
2005-03-01 |
Smithkline Beecham Pharma Gmbh |
Novel vaccine composition
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
CA2452382A1
(en)
|
2001-07-10 |
2003-01-23 |
Corixa Corporation |
Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
EP2272530A3
(en)
*
|
2001-07-26 |
2013-05-22 |
Otago Innovation Limited |
Antigenic Compositions
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
GB0118367D0
(en)
|
2001-07-27 |
2001-09-19 |
Glaxosmithkline Biolog Sa |
Novel use
|
US20030138434A1
(en)
*
|
2001-08-13 |
2003-07-24 |
Campbell Robert L. |
Agents for enhancing the immune response
|
US7361352B2
(en)
|
2001-08-15 |
2008-04-22 |
Acambis, Inc. |
Influenza immunogen and vaccine
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
EP1581119B1
(en)
|
2001-12-17 |
2013-01-30 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
US7030094B2
(en)
*
|
2002-02-04 |
2006-04-18 |
Corixa Corporation |
Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
|
EP2572707A3
(en)
|
2002-02-20 |
2013-11-06 |
Novartis Vaccines and Diagnostics, Inc. |
Microparticles with adsorbed polypeptide-containing molecules
|
US7351413B2
(en)
|
2002-02-21 |
2008-04-01 |
Lorantis, Limited |
Stabilized HBc chimer particles as immunogens for chronic hepatitis
|
GB0206360D0
(en)
|
2002-03-18 |
2002-05-01 |
Glaxosmithkline Biolog Sa |
Viral antigens
|
PL209696B1
(pl)
|
2002-04-19 |
2011-10-31 |
Univ Toronto |
Peptyd, kompozycja peptydowa, kompozycja immunogenna, zastosowania kompozycji immunogennej oraz sposób określania czy związek stanowi inhbitor odkładania się i tworzenia włókienek amyloidu
|
US20030224013A1
(en)
*
|
2002-04-19 |
2003-12-04 |
Cole Garry T. |
Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
|
ATE545651T1
(de)
|
2002-06-13 |
2012-03-15 |
Novartis Vaccines & Diagnostic |
Vektoren zur expression von hml-2-polypeptiden
|
DK2011510T3
(da)
|
2002-07-18 |
2011-03-28 |
Univ Washington |
Farmaceutiske sammensætninger indeholdende immunologisk aktive Herpes simplex-virus(HSV) proteinfragmenter
|
MXPA05001265A
(es)
|
2002-08-02 |
2005-04-28 |
Glaxosmithkline Biolog Sa |
Composiciones de vacuna de neisserial que comprenden una combinacion de antigenos.
|
JP4726485B2
(ja)
*
|
2002-08-02 |
2011-07-20 |
大日本住友製薬株式会社 |
細菌細胞壁骨格成分製剤
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
US7169548B2
(en)
|
2002-09-13 |
2007-01-30 |
Xy, Inc. |
Sperm cell processing and preservation systems
|
HUE047780T2
(hu)
|
2002-10-11 |
2020-05-28 |
Glaxosmithkline Biologicals Sa |
Polipeptid vakcinák hipervirulens meningokokkusz vonalak elleni széles-spektrumú védelemre
|
CA2502268A1
(en)
|
2002-10-23 |
2004-05-06 |
Glaxosmithkline Biologicals S.A. |
Methods for vaccinating against malaria
|
DK2279746T3
(da)
|
2002-11-15 |
2013-11-25 |
Novartis Vaccines & Diagnostic |
Overfladeproteiner i neisseria meningitidis
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
US7858098B2
(en)
|
2002-12-20 |
2010-12-28 |
Glaxosmithkline Biologicals, S.A. |
Vaccine
|
EP1581812B1
(en)
|
2003-01-06 |
2008-07-16 |
Wyeth |
Compositions and methods for diagnosing and treating colon cancers
|
CN102302776B
(zh)
|
2003-01-30 |
2014-06-18 |
诺华疫苗和诊断有限公司 |
抗多种脑膜炎球菌血清组的可注射性疫苗
|
ES2918578T3
(es)
|
2003-03-28 |
2022-07-19 |
Inguran Llc |
Aparato y métodos para proporcionar esperma animal clasificado por sexo
|
SI1613346T1
(sl)
|
2003-04-04 |
2013-02-28 |
Pah Usa 15 Llc |
Mikrofluidizirane emulzije olja v vodi in sestava cepiv
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
US7731967B2
(en)
*
|
2003-04-30 |
2010-06-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions for inducing immune responses
|
DE602004022286D1
(de)
|
2003-06-02 |
2009-09-10 |
Novartis Vaccines & Diagnostic |
Immunogene zusammensetzungen auf basis von biologisch abbaubaren mikroteilchen enthaltend ein diphtherie- und ein tetanustoxoid
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
CA2539715C
(en)
|
2003-10-02 |
2015-02-24 |
Glaxosmithkline Biologicals S.A. |
Pertussis antigens and use thereof in vaccination
|
NZ546430A
(en)
|
2003-10-02 |
2009-04-30 |
Novartis Vaccines & Diagnostic |
Liquid vaccines for multiple meningococcal serogroups
|
EP1730182B1
(en)
|
2004-02-05 |
2015-04-29 |
The Ohio State University Research Foundation |
Chimeric vegf peptides
|
WO2005107797A1
(en)
|
2004-03-09 |
2005-11-17 |
Chiron Corporation |
Influenza virus vaccines
|
US20080032384A1
(en)
*
|
2004-04-22 |
2008-02-07 |
Takehiko Nomura |
Pharmaceutical Preparation Containing Bacterial Cell Wall Skeleton
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
EP2272531A3
(en)
|
2004-04-30 |
2011-04-13 |
Novartis Vaccines and Diagnostics S.r.l. |
Integration of meningococcal conjugate vaccination
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
ES2647491T3
(es)
|
2004-05-21 |
2017-12-21 |
Novartis Vaccines And Diagnostics, Inc. |
Vectores del alfavirus para las vacunas del virus de la gripe
|
CA2567597C
(en)
|
2004-05-25 |
2014-03-18 |
Oregon Health And Science University |
Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
|
EP2269638A3
(en)
|
2004-05-28 |
2012-06-13 |
GlaxoSmithKline Biologicals S.A. |
Vaccine compositions comprising virosomes and a saponin adjuvant
|
US7758866B2
(en)
|
2004-06-16 |
2010-07-20 |
Glaxosmithkline Biologicals, S.A. |
Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
|
US8085126B2
(en)
*
|
2004-07-27 |
2011-12-27 |
Honeywell International Inc. |
Identification with RFID asset locator for entry authorization
|
EP2612679A1
(en)
|
2004-07-29 |
2013-07-10 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0417494D0
(en)
|
2004-08-05 |
2004-09-08 |
Glaxosmithkline Biolog Sa |
Vaccine
|
BRPI0515516B1
(pt)
|
2004-09-22 |
2017-08-08 |
Glaxosmithkline Biologicals S.A. |
Immunogenic composition, vaccine, method of manufacturing a vaccine, and, use of immunogenic composition.
|
EP3312272B1
(en)
|
2004-10-08 |
2019-08-28 |
The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services |
Modulation of replicative fitness by using less frequently used synonymous codons
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
AR052051A1
(es)
|
2004-12-15 |
2007-02-28 |
Neuralab Ltd |
Anticuerpos ab humanizados usados en mejorar la cognicion
|
US9034345B2
(en)
|
2005-01-27 |
2015-05-19 |
Children's Hospital & Research Center Oakland |
GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
GB0503337D0
(en)
|
2005-02-17 |
2005-03-23 |
Glaxosmithkline Biolog Sa |
Compositions
|
NZ560929A
(en)
|
2005-02-18 |
2009-12-24 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic escherichia coli
|
PL2351772T3
(pl)
|
2005-02-18 |
2017-01-31 |
Glaxosmithkline Biologicals Sa |
Białka i kwasy nukleinowe z bakterii Escherichia coli związanej z zapaleniem opon mózgowo-rdzeniowych/posocznicą
|
GB0504436D0
(en)
|
2005-03-03 |
2005-04-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
AR053833A1
(es)
*
|
2005-03-23 |
2007-05-23 |
Glaxosmithkline Biolog Sa |
Composicion inmunogenetica
|
GB0506001D0
(en)
*
|
2005-03-23 |
2005-04-27 |
Glaxosmithkline Biolog Sa |
Novel use
|
BRPI0609547A2
(pt)
|
2005-03-31 |
2011-10-18 |
Glaxosmithkline Biolog Sa |
composição, uso de uma composição, método para o tratamento ou prevenção de infecção por chlamydia, uso de uma ou mais proteìnas de chlamydia, de fragmentos imunogênicos das mesmas ou de polinucleotìdeos codificando os mesmos, método para o tratamento ou prevenção de infecção por chlamydia, e, método para a determinação prévia de infecção por chlamydia em um indivìduo
|
US20070292418A1
(en)
*
|
2005-04-26 |
2007-12-20 |
Eisai Co., Ltd. |
Compositions and methods for immunotherapy
|
CN103285392A
(zh)
*
|
2005-04-26 |
2013-09-11 |
卫材R&D管理株式会社 |
用于癌症免疫疗法的组合物和其用途
|
KR20120089475A
(ko)
|
2005-04-29 |
2012-08-10 |
인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) |
결핵균 감염을 예방 또는 치료하기 위한 신규한 방법
|
EP1912680B1
(en)
|
2005-06-15 |
2014-11-26 |
The Ohio State University Research Foundation |
Her-2 peptides
|
GB0513421D0
(en)
|
2005-06-30 |
2005-08-03 |
Glaxosmithkline Biolog Sa |
Vaccines
|
ATE530569T1
(de)
|
2005-07-01 |
2011-11-15 |
Forsyth Dental In Ry For Children Fa |
Assays zum nachweis von tuberkulose- antigenen, und impfstoffe
|
WO2007041314A2
(en)
*
|
2005-09-30 |
2007-04-12 |
Tti Ellebeau, Inc. |
Transdermal drug delivery systems, devices, and methods employing novel pharmaceutical vehicles
|
KR20080066712A
(ko)
*
|
2005-09-30 |
2008-07-16 |
티티아이 엘뷰 가부시키가이샤 |
관능화된 미세바늘 경피 약물 전달 시스템, 장치 및 방법
|
GB0519871D0
(en)
|
2005-09-30 |
2005-11-09 |
Secr Defence |
Immunogenic agents
|
US20070078376A1
(en)
*
|
2005-09-30 |
2007-04-05 |
Smith Gregory A |
Functionalized microneedles transdermal drug delivery systems, devices, and methods
|
EP2357000A1
(en)
|
2005-10-18 |
2011-08-17 |
Novartis Vaccines and Diagnostics, Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
US11707520B2
(en)
|
2005-11-03 |
2023-07-25 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
US20110180430A1
(en)
*
|
2005-11-04 |
2011-07-28 |
Novartis Vaccines And Diagnostics Srl |
Adjuvanted influenza vaccines including cytokine-inducing agents
|
CA2628158C
(en)
*
|
2005-11-04 |
2015-12-15 |
Novartis Vaccines And Diagnostics S.R.L. |
Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
|
CA2628206A1
(en)
|
2005-11-04 |
2007-05-10 |
Novartis Vaccines And Diagnostics S.R.L. |
Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
|
EP3714900A1
(en)
|
2005-11-04 |
2020-09-30 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
GB0522765D0
(en)
|
2005-11-08 |
2005-12-14 |
Chiron Srl |
Combination vaccine manufacture
|
JP5492418B2
(ja)
*
|
2005-11-18 |
2014-05-14 |
ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション |
ウイルス関連疾患を予防するためのウイルス遺伝子産物およびワクチン接種の方法
|
CA2629193C
(en)
*
|
2005-11-18 |
2016-03-29 |
3M Innovative Properties Company |
Coatable compositions, coatings derived therefrom and microarrays having such coatings
|
US7527801B2
(en)
|
2005-11-22 |
2009-05-05 |
Novartis Vaccines And Diagnostics, Inc. |
Norovirus and Sapovirus antigens
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
TWI457133B
(zh)
*
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
TWI465248B
(zh)
|
2005-12-22 |
2014-12-21 |
Glaxosmithkline Biolog Sa |
包含莢膜醣結合物之肺炎鏈球菌免疫原組合物、包含其之疫苗及套組及其用途
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
US20080033398A1
(en)
*
|
2005-12-29 |
2008-02-07 |
Transcutaneous Technologies Inc. |
Device and method for enhancing immune response by electrical stimulation
|
KR20080096775A
(ko)
|
2006-01-17 |
2008-11-03 |
아르네 포르스그렌 |
표면 노출된 헤모필루스 인플루엔자 단백질 (단백질 E ―pE)
|
BR122019013216B8
(pt)
|
2006-01-27 |
2021-07-27 |
Seqirus Uk Ltd |
ensaio imunológico para análise de uma vacina contra influenza
|
EP2357184B1
(en)
|
2006-03-23 |
2015-02-25 |
Novartis AG |
Imidazoquinoxaline compounds as immunomodulators
|
ES2388556T3
(es)
|
2006-03-23 |
2012-10-16 |
Novartis Ag |
Compuestos inmunopotenciadores
|
CA2646349A1
(en)
|
2006-03-24 |
2007-10-04 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg |
Storage of influenza vaccines without refrigeration
|
AU2007245198B2
(en)
|
2006-03-30 |
2010-08-12 |
Zoetis Services Llc |
Methods and compositions for vaccination of poultry
|
EP2476434A1
(en)
|
2006-03-30 |
2012-07-18 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic composition
|
US9839685B2
(en)
|
2006-04-13 |
2017-12-12 |
The Regents Of The University Of Michigan |
Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
|
US10138279B2
(en)
|
2006-04-13 |
2018-11-27 |
Regents Of The University Of Michigan |
Compositions and methods for Bacillus anthracis vaccination
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
EP2392672A1
(en)
|
2006-06-02 |
2011-12-07 |
GlaxoSmithKline Biologicals S.A. |
Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the CD52 gene
|
US20110206692A1
(en)
|
2006-06-09 |
2011-08-25 |
Novartis Ag |
Conformers of bacterial adhesins
|
ES2337309T5
(es)
|
2006-06-12 |
2013-07-30 |
Glaxosmithkline Biologicals S.A. |
Vacuna
|
US8128921B2
(en)
*
|
2006-07-11 |
2012-03-06 |
University Of Connecticut |
Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
|
US8153116B2
(en)
|
2006-07-11 |
2012-04-10 |
University Of Connecticut |
Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
|
KR101696727B1
(ko)
*
|
2006-07-17 |
2017-01-16 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
인플루엔자 백신
|
DK2422810T3
(da)
|
2006-07-17 |
2014-11-24 |
Glaxosmithkline Biolog Sa |
Influenzavaccine
|
US9592282B2
(en)
|
2006-07-18 |
2017-03-14 |
Glaxosmithkline Biologicals Sa |
Vaccines for malaria
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
EP2040744B1
(en)
|
2006-07-25 |
2016-03-09 |
The Secretary of State for Defence |
Live vaccine strains of francisella
|
EP2586790A3
(en)
|
2006-08-16 |
2013-08-14 |
Novartis AG |
Immunogens from uropathogenic Escherichia coli
|
KR20090064412A
(ko)
*
|
2006-09-01 |
2009-06-18 |
씨에스엘 리미티드 |
면역 반응을 유발 또는 유도하는 방법
|
ATE511398T1
(de)
|
2006-09-07 |
2011-06-15 |
Glaxosmithkline Biolog Sa |
Inaktiviertes poliovirus mischimpfstoff
|
EP3456348A1
(en)
|
2006-09-11 |
2019-03-20 |
Seqirus UK Limited |
Making influenza virus vaccines without using eggs
|
EP3795173A1
(en)
|
2006-09-26 |
2021-03-24 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
EP2086582B1
(en)
|
2006-10-12 |
2012-11-14 |
GlaxoSmithKline Biologicals s.a. |
Vaccine comprising an oil in water emulsion adjuvant
|
WO2008043774A1
(en)
|
2006-10-12 |
2008-04-17 |
Glaxosmithkline Biologicals S.A. |
Vaccine comprising an oil in water emulsion adjuvant
|
GB0622282D0
(en)
|
2006-11-08 |
2006-12-20 |
Novartis Ag |
Quality control methods
|
CN101553252A
(zh)
|
2006-12-06 |
2009-10-07 |
诺华有限公司 |
包含来自于四株流感病毒的抗原的疫苗
|
US20100055166A1
(en)
|
2007-03-02 |
2010-03-04 |
Gerald Hermann Voss |
Novel method and compositions
|
US8486414B2
(en)
|
2007-04-04 |
2013-07-16 |
Infectious Disease Research Institute |
Immunogenic compositions comprising Mycobacterium tuberculosis polypeptides and fusions thereof
|
PE20090146A1
(es)
|
2007-04-20 |
2009-03-23 |
Glaxosmithkline Biolog Sa |
Composicion inmunogenica contra el virus influenza
|
MX2009011837A
(es)
|
2007-05-02 |
2010-04-22 |
Glaxosmithkline Biolog Sa |
Vacuna.
|
GB0711858D0
(en)
*
|
2007-06-19 |
2007-07-25 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EA200901578A1
(ru)
|
2007-06-26 |
2010-08-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
|
AU2008269439B2
(en)
|
2007-06-27 |
2013-12-19 |
Novartis Ag |
Low-additive influenza vaccines
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
CA2695399C
(en)
|
2007-08-02 |
2017-10-17 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope influenza vaccines
|
WO2009020553A2
(en)
|
2007-08-03 |
2009-02-12 |
President And Fellows Of Harvard College |
Chlamydia antigens
|
AR067905A1
(es)
|
2007-08-13 |
2009-10-28 |
Glaxosmithkline Biolog Sa |
Vacunas
|
AU2008299376B2
(en)
|
2007-09-12 |
2013-02-28 |
Glaxosmithkline Biologicals S.A. |
GAS57 mutant antigens and GAS57 antibodies
|
EP2201131B8
(en)
|
2007-09-17 |
2014-12-10 |
MDxHealth SA |
Improved methylation detection
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
EP2722056A1
(en)
|
2007-12-03 |
2014-04-23 |
President and Fellows of Harvard College |
CT062, a Chlamydia antigen
|
US8668904B2
(en)
|
2007-12-06 |
2014-03-11 |
Glaxosmithkline Biologicals S.A. |
Influenza composition
|
EP3067048B1
(en)
*
|
2007-12-07 |
2018-02-14 |
GlaxoSmithKline Biologicals SA |
Compositions for inducing immune responses
|
EP2227483B1
(en)
|
2007-12-19 |
2017-04-19 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
KR101773114B1
(ko)
|
2007-12-21 |
2017-08-30 |
노파르티스 아게 |
스트렙토라이신 o의 돌연변이 형태
|
US8092813B1
(en)
|
2007-12-28 |
2012-01-10 |
Novartis Ag |
Polychlorinated biphenyls and squalene-containing adjuvants
|
AU2009215364B2
(en)
|
2008-02-21 |
2014-09-18 |
Glaxosmithkline Biologicals S.A. |
Meningococcal fHBP polypeptides
|
EP2631245A1
(en)
|
2008-03-10 |
2013-08-28 |
Children's Hospital & Research Center at Oakland |
Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
|
EP2283138A4
(en)
*
|
2008-04-09 |
2011-05-11 |
Ventria Bioscience |
OSPA PRODUCTION FOR THE FIGHT AGAINST LYME DISEASE
|
EP2271360B1
(en)
|
2008-04-16 |
2015-09-23 |
GlaxoSmithKline Biologicals S.A. |
Vaccine
|
ES2922534T3
(es)
|
2008-04-18 |
2022-09-16 |
Massachusetts Gen Hospital |
Inmunoterapias que emplean vacunas autoensamblantes
|
US9415006B2
(en)
|
2008-05-23 |
2016-08-16 |
The Regents Of The University Of Michigan |
Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
|
WO2009147980A1
(ja)
|
2008-06-04 |
2009-12-10 |
財団法人化学及血清療法研究所 |
不活化日本脳炎ウイルス粒子をアジュバントとして使用する方法
|
WO2009155489A2
(en)
|
2008-06-19 |
2009-12-23 |
Variation Biotechnologies, Inc. |
Compositions and methods for treating influenza
|
RU2011107757A
(ru)
|
2008-08-01 |
2012-09-10 |
Гамма Ваксинс Пти Лимитед (Au) |
Вакцины против гриппа
|
ES2761697T3
(es)
|
2008-08-28 |
2020-05-20 |
Novartis Ag |
Proceso para preparar una emulsión de aceite en agua que contiene escualeno procedente de levaduras
|
GB0815872D0
(en)
|
2008-09-01 |
2008-10-08 |
Pasteur Institut |
Novel method and compositions
|
AU2009296458A1
(en)
|
2008-09-26 |
2010-04-01 |
Nanobio Corporation |
Nanoemulsion therapeutic compositions and methods of using the same
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
EP2376089B1
(en)
|
2008-11-17 |
2018-03-14 |
The Regents of the University of Michigan |
Cancer vaccine compositions and methods of using the same
|
GB0822001D0
(en)
*
|
2008-12-02 |
2009-01-07 |
Glaxosmithkline Biolog Sa |
Vaccine
|
CA2745205A1
(en)
|
2008-12-03 |
2010-06-10 |
Protea Vaccine Technologies Ltd. |
Glutamyl trna synthetase (gts) fragments
|
MX337723B
(es)
|
2008-12-09 |
2016-03-15 |
Pfizer Vaccines Llc |
Vacuna de peptido ch3 de ige.
|
US9884105B2
(en)
|
2008-12-16 |
2018-02-06 |
Ology Bioservices, Inc. |
Production of viral vaccine
|
CA2749367A1
(en)
|
2009-01-12 |
2010-07-15 |
Novartis Ag |
Cna_b domain antigens in vaccines against gram positive bacteria
|
GB0900455D0
(en)
|
2009-01-13 |
2009-02-11 |
Secr Defence |
Vaccine
|
GB0901423D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
GB0901411D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
US20100234283A1
(en)
|
2009-02-04 |
2010-09-16 |
The Ohio State University Research Foundation |
Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
|
DK2396032T3
(en)
|
2009-02-10 |
2016-12-19 |
Seqirus Uk Ltd |
Influenza vaccines with reduced amounts of squalene
|
AU2010215595A1
(en)
*
|
2009-02-17 |
2011-08-25 |
Glaxosmithkline Biologicals S.A. |
Inactivated dengue virus vaccine with aluminium-free adjuvant
|
WO2010100632A2
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Ag |
Chlamydia antigens
|
EP2408933A2
(en)
|
2009-03-17 |
2012-01-25 |
MDxHealth SA |
Improved detection of gene expression
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
SG175092A1
(en)
|
2009-04-14 |
2011-11-28 |
Novartis Ag |
Compositions for immunising against staphylococcus aerus
|
KR101450958B1
(ko)
|
2009-04-30 |
2014-10-15 |
콜레이 파마시티컬 그룹, 인코포레이티드 |
폐렴구균 백신 및 그의 용도
|
US8668911B2
(en)
|
2009-05-14 |
2014-03-11 |
The Regents Of The University Of Michigan |
Streptococcus vaccine compositions and methods of using the same
|
KR20120014054A
(ko)
|
2009-05-27 |
2012-02-15 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
Casb7439 작제물
|
AU2010256461B2
(en)
|
2009-06-05 |
2016-03-17 |
Access To Advanced Health Institute |
Synthetic glucopyranosyl lipid adjuvants
|
JP5551774B2
(ja)
|
2009-06-15 |
2014-07-16 |
ナショナル ユニヴァーシティー オブ シンガポール |
インフルエンザワクチン、組成物、および使用方法
|
WO2010148111A1
(en)
|
2009-06-16 |
2010-12-23 |
The Regents Of The University Of Michigan |
Nanoemulsion vaccines
|
CN102482666B
(zh)
|
2009-07-06 |
2017-02-08 |
变异生物技术公司 |
制备囊泡的方法和由其产生的制剂
|
US9907746B2
(en)
|
2009-07-06 |
2018-03-06 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
SG177533A1
(en)
|
2009-07-07 |
2012-02-28 |
Novartis Ag |
Conserved escherichia coli immunogens
|
RU2585227C2
(ru)
|
2009-07-15 |
2016-05-27 |
Новартис Аг |
Композиции белка f rsv и способы их получения
|
ES2526996T3
(es)
|
2009-07-16 |
2015-01-19 |
Novartis Ag |
Inmunógenos desintoxicados de Escherichia coli
|
JP5646620B2
(ja)
|
2009-07-17 |
2014-12-24 |
インダストリー アカデミック コーポレーション ファウンデーション, ハルリム ユニバーシティー |
リポソームに被包されたオリゴヌクレオチド及びエピトープを含む免疫増強用組成物
|
MX2012001194A
(es)
|
2009-07-30 |
2012-03-07 |
Pfizer Vaccines Llc |
Peptidos tau antigenicos y usos de los mismos.
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0913681D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
BR112012004275A2
(pt)
|
2009-08-27 |
2016-11-16 |
Novartis Ag |
polipeptídios híbridos incluindo sequências meningocócicas de fhbp
|
EP2865752A1
(en)
|
2009-09-03 |
2015-04-29 |
Pfizer Vaccines LLC |
PCSK9 vaccine
|
MY157607A
(en)
*
|
2009-09-10 |
2016-06-30 |
Merial Inc |
New vaccine formulations comprising saponin-containing adjuvants
|
CA2773637A1
(en)
|
2009-09-10 |
2011-03-17 |
Novartis Ag |
Combination vaccines against respiratory tract diseases
|
GB0917457D0
(en)
|
2009-10-06 |
2009-11-18 |
Glaxosmithkline Biolog Sa |
Method
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
GB0917003D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Purification of bacterial vesicles
|
RU2603267C2
(ru)
|
2009-09-30 |
2016-11-27 |
Новартис Аг |
Конъюгация капсульных полисахаридов staphylococcus aureus типа 5 и типа 8
|
CN102724988B
(zh)
|
2009-09-30 |
2014-09-10 |
诺华股份有限公司 |
脑膜炎球菌fHBP多肽的表达
|
SG10201505023TA
(en)
|
2009-10-09 |
2015-07-30 |
Cbio Ltd |
Chaperonin 10 Variants
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
CN102917730A
(zh)
|
2009-10-27 |
2013-02-06 |
诺华有限公司 |
修饰的脑膜炎球菌fHBP多肽
|
GB0918830D0
(en)
|
2009-10-27 |
2009-12-09 |
Glaxosmithkline Biolog Niederl |
Process
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
WO2011067758A2
(en)
|
2009-12-02 |
2011-06-09 |
Protea Vaccine Technologies Ltd. |
Immunogenic fragments and multimers from streptococcus pneumoniae proteins
|
CN107412754A
(zh)
|
2009-12-22 |
2017-12-01 |
塞尔德克斯医疗公司 |
疫苗组合物
|
US20110159031A1
(en)
|
2009-12-22 |
2011-06-30 |
Baxter International Inc. |
Vaccine to Influenza A Virus
|
US9173954B2
(en)
|
2009-12-30 |
2015-11-03 |
Glaxosmithkline Biologicals Sa |
Polysaccharide immunogens conjugated to E. coli carrier proteins
|
EP2353609A1
(en)
|
2010-02-04 |
2011-08-10 |
Sanofi Pasteur |
Immunization compositions and methods
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201003920D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Method of treatment
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
CN103002910A
(zh)
|
2010-03-10 |
2013-03-27 |
葛兰素史密丝克莱恩生物有限公司 |
疫苗组合物
|
SG183514A1
(en)
|
2010-03-11 |
2012-10-30 |
Immune Design Corp |
Vaccines for pandemic influenza
|
WO2011117408A1
(en)
|
2010-03-26 |
2011-09-29 |
Glaxosmithkline Biologicals S.A. |
Hiv vaccine
|
CN110845585A
(zh)
|
2010-03-30 |
2020-02-28 |
奥克兰儿童医院及研究中心 |
改性的h因子结合蛋白(fhbp)及其使用方法
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2011127316A1
(en)
|
2010-04-07 |
2011-10-13 |
Novartis Ag |
Method for generating a parvovirus b19 virus-like particle
|
GB201006324D0
(en)
|
2010-04-15 |
2010-06-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
KR20130121699A
(ko)
|
2010-05-28 |
2013-11-06 |
테트리스 온라인, 인코포레이티드 |
상호작용 혼성 비동기 컴퓨터 게임 기반구조
|
DK2575870T3
(en)
|
2010-06-04 |
2017-02-13 |
Wyeth Llc |
vaccine Formulations
|
EP2575868A1
(en)
|
2010-06-07 |
2013-04-10 |
Pfizer Vaccines LLC |
Ige ch3 peptide vaccine
|
US8895017B2
(en)
|
2010-06-07 |
2014-11-25 |
Pfizer Inc. |
HER-2 peptides and vaccines
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
WO2012006293A1
(en)
|
2010-07-06 |
2012-01-12 |
Novartis Ag |
Norovirus derived immunogenic compositions and methods
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
JP6119030B2
(ja)
|
2010-07-06 |
2017-04-26 |
ヴァリエーション バイオテクノロジーズ インコーポレイテッド |
インフルエンザを治療するための組成物及び方法
|
GB201015132D0
(en)
|
2010-09-10 |
2010-10-27 |
Univ Bristol |
Vaccine composition
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
US20130259948A1
(en)
|
2010-09-21 |
2013-10-03 |
National Institute Of Immunology |
Spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles
|
US9168292B2
(en)
|
2010-09-27 |
2015-10-27 |
Crucell Holland B.V. |
Heterologous prime boost vaccination regimen against malaria
|
CA2812893A1
(en)
|
2010-09-27 |
2012-04-05 |
Glaxosmithkline Biologicals S.A. |
Vaccine
|
GB201017519D0
(en)
|
2010-10-15 |
2010-12-01 |
Novartis Vaccines Inst For Global Health S R L |
Vaccines
|
WO2012057904A1
(en)
|
2010-10-27 |
2012-05-03 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
GB201101331D0
(en)
|
2011-01-26 |
2011-03-09 |
Glaxosmithkline Biolog Sa |
Compositions and uses
|
EP2637687B1
(en)
|
2010-11-08 |
2021-01-06 |
Infectious Disease Research Institute |
Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
WO2012072088A1
(en)
|
2010-12-02 |
2012-06-07 |
Bionor Immuno As |
Peptide scaffold design
|
US20130315959A1
(en)
|
2010-12-24 |
2013-11-28 |
Novartis Ag |
Compounds
|
GB201022007D0
(en)
|
2010-12-24 |
2011-02-02 |
Imp Innovations Ltd |
DNA-sensor
|
AU2012204955B2
(en)
|
2011-01-06 |
2016-10-06 |
Bionor Immuno As |
Monomeric and multimeric immunogenic peptides
|
CN103501811B
(zh)
|
2011-01-13 |
2016-03-30 |
变异生物技术公司 |
用于治疗病毒感染的组合物和方法
|
CN103533923A
(zh)
|
2011-01-13 |
2014-01-22 |
变异生物技术公司 |
囊泡及由其产生之制剂的制备方法
|
EP2667892B1
(en)
|
2011-01-26 |
2019-03-27 |
GlaxoSmithKline Biologicals SA |
Rsv immunization regimen
|
US20140079732A1
(en)
|
2011-01-27 |
2014-03-20 |
Gamma Vaccines Pty Limited |
Combination vaccines
|
WO2012114323A1
(en)
|
2011-02-22 |
2012-08-30 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
|
EP2680883B1
(en)
|
2011-03-02 |
2018-09-05 |
Pfizer Inc |
Pcsk9 vaccine
|
EP2691422B1
(en)
|
2011-03-29 |
2019-02-06 |
UAB Research Foundation |
Methods and compositions for cytomegalovirus il-10 protein
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
EP3632463A1
(en)
|
2011-04-08 |
2020-04-08 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
TW201302779A
(zh)
|
2011-04-13 |
2013-01-16 |
Glaxosmithkline Biolog Sa |
融合蛋白質及組合疫苗
|
US20120288515A1
(en)
|
2011-04-27 |
2012-11-15 |
Immune Design Corp. |
Synthetic long peptide (slp)-based vaccines
|
SG194755A1
(en)
|
2011-05-13 |
2013-12-30 |
Novartis Ag |
Pre-fusion rsv f antigens
|
WO2012156391A1
(en)
|
2011-05-17 |
2012-11-22 |
Glaxosmithkline Biologicals S.A. |
Vaccine against streptococcus pneumoniae
|
CA2838188C
(en)
|
2011-06-04 |
2017-04-18 |
Rochester General Hospital Research Institute |
Compositions and methods related to p6 of haemophilus influenzae
|
WO2012177595A1
(en)
|
2011-06-21 |
2012-12-27 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
JP6109165B2
(ja)
*
|
2011-07-01 |
2017-04-05 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ヘルペスウイルスワクチンおよび使用方法
|
EP2736921B1
(en)
|
2011-07-25 |
2018-06-27 |
GlaxoSmithKline Biologicals SA |
Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
|
GB201113570D0
(en)
|
2011-08-05 |
2011-09-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
CA2845872C
(en)
|
2011-08-22 |
2023-03-28 |
Nanobio Corporation |
Herpes simplex virus nanoemulsion vaccine
|
GB201114919D0
(en)
|
2011-08-30 |
2011-10-12 |
Glaxosmithkline Biolog Sa |
Method
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
CA2848163C
(en)
|
2011-09-09 |
2020-10-27 |
Nanobio Corporation |
Nanoemulsion respiratory syncytial virus (rsv) subunit vaccine
|
CN103930436A
(zh)
|
2011-09-14 |
2014-07-16 |
诺华股份有限公司 |
大肠杆菌疫苗组合
|
TR201909110T4
(tr)
|
2011-09-14 |
2019-07-22 |
Glaxosmithkline Biologicals Sa |
Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler.
|
CN108424449A
(zh)
|
2011-09-16 |
2018-08-21 |
Ucb医药有限公司 |
针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体
|
US20130122038A1
(en)
|
2011-11-14 |
2013-05-16 |
The United States Of America As Represented By The Secretary Of The Department |
Heterologous prime-boost immunization using measles virus-based vaccines
|
US9902760B2
(en)
|
2011-11-23 |
2018-02-27 |
Bioven 3 Limited |
Recombinant proteins and their therapeutic uses
|
WO2013083753A2
(en)
|
2011-12-07 |
2013-06-13 |
Institut Pasteur |
Identification of a swine parecho-like virus and applications
|
RU2014127714A
(ru)
|
2011-12-08 |
2016-01-27 |
Новартис Аг |
ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
|
CN104302323A
(zh)
|
2012-01-12 |
2015-01-21 |
变异生物技术公司 |
用于治疗病毒感染的组合物和方法
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
EP4008354A1
(en)
|
2012-01-27 |
2022-06-08 |
Variation Biotechnologies Inc. |
Methods and compositions for therapeutic agents
|
TR201908003T4
(tr)
|
2012-02-07 |
2019-06-21 |
Infectious Disease Res Inst |
TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları.
|
JP2015509713A
(ja)
|
2012-02-24 |
2015-04-02 |
ノバルティス アーゲー |
線毛タンパク質および組成物
|
US20130236484A1
(en)
|
2012-03-08 |
2013-09-12 |
Detectogen Inc. |
Leishmaniasis antigen detection assays and vaccines
|
EP3061451B1
(en)
|
2012-03-23 |
2019-05-08 |
Pitney Pharmaceuticals Pty Limited |
Kinase inhibitors for the treatment of cancer
|
GB201205189D0
(en)
|
2012-03-23 |
2012-05-09 |
Glaxosmithkline Biolog Sa |
Novel medical use
|
WO2013150518A1
(en)
|
2012-04-01 |
2013-10-10 |
Rappaport Family Institute For Research In The Medical Sciences |
Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
|
WO2013151764A1
(en)
|
2012-04-02 |
2013-10-10 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for dengue virus epitopes
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
WO2013160335A2
(en)
|
2012-04-26 |
2013-10-31 |
Novartis Ag |
Antigens and antigen combinations
|
EP2659908A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659907A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659906A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
WO2013164754A2
(en)
|
2012-05-04 |
2013-11-07 |
Pfizer Inc. |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
RS57420B1
(sr)
|
2012-05-16 |
2018-09-28 |
Immune Design Corp |
Vakcine za hsv-2
|
RU2014151567A
(ru)
|
2012-05-22 |
2016-07-10 |
Новартис Аг |
Конъюгат менингококка серогруппы х
|
EP2666785A1
(en)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Complement component C5a-based vaccine
|
US20150150963A1
(en)
|
2012-06-05 |
2015-06-04 |
The Australian National University |
Vaccination with interleukin-4 antagonists
|
NZ702146A
(en)
|
2012-06-06 |
2016-11-25 |
Bionor Immuno As |
Peptides derived from viral proteins for use as immunogens and dosage reactants
|
WO2014016360A1
(en)
|
2012-07-24 |
2014-01-30 |
Sanofi Pasteur |
Vaccine compositions
|
MX2015000446A
(es)
|
2012-07-24 |
2015-03-12 |
Sanofi Pasteur |
Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue.
|
MX362511B
(es)
|
2012-08-01 |
2019-01-22 |
Bavarian Nordic As |
Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr).
|
PT2879701T
(pt)
|
2012-08-03 |
2024-02-12 |
Access To Advanced Health Inst |
Composições e métodos para o tratamento de uma infeção ativa por mycobacterium tuberculosis
|
CN104837812B
(zh)
|
2012-08-06 |
2017-09-26 |
皮特尼制药股份有限公司 |
治疗mTOR通路相关的疾病的化合物
|
JP2014040396A
(ja)
*
|
2012-08-23 |
2014-03-06 |
Chemo-Sero-Therapeutic Research Institute |
脂質異常症治療薬を含有するアジュバント組成物
|
EP2703483A1
(en)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
PCSK9 peptide vaccine
|
US10232035B2
(en)
|
2012-09-14 |
2019-03-19 |
The Regents Of The University Of Colorado, A Body Corporate |
Conditionally replication deficient herpes virus and use thereof in vaccines
|
EP4056198A3
(en)
|
2012-09-18 |
2022-12-07 |
GlaxoSmithKline Biologicals SA |
Outer membrane vesicles
|
AU2013326584B2
(en)
|
2012-10-02 |
2016-12-01 |
Glaxosmithkline Biologicals Sa |
Nonlinear saccharide conjugates
|
US9855325B2
(en)
|
2012-10-03 |
2018-01-02 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
DK2912186T3
(da)
|
2012-10-24 |
2021-02-22 |
Platelet Targeted Therapeutics Llc |
Behandling rettet mod blodplader
|
US9987344B2
(en)
|
2012-11-30 |
2018-06-05 |
Glaxosmithkline Biologicals Sa |
Pseudomonas antigens and antigen combinations
|
BR112015012515B1
(pt)
|
2012-11-30 |
2023-04-11 |
Sanofi Pasteur |
Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
|
HUE061273T2
(hu)
|
2012-12-05 |
2023-06-28 |
Glaxosmithkline Biologicals Sa |
Immunogén készítmény
|
CA2895149C
(en)
|
2012-12-17 |
2023-08-22 |
Pitney Pharmaceuticals Pty Limited |
Treatment of diseases involving mucin
|
JP6286445B2
(ja)
|
2012-12-24 |
2018-02-28 |
セル・アイディアズ・ピーティーワイ・リミテッド |
がんの治療のためのワクチン及びワクチン有効性を増強するための組成物
|
AU2014214844B2
(en)
|
2013-02-07 |
2017-12-14 |
Children's Medical Center Corporation |
Protein antigens that provide protection against pneumococcal colonization and/or disease
|
CN111978409B
(zh)
|
2013-03-15 |
2024-01-26 |
因斯瑞拜奥有限公司 |
自组装合成蛋白
|
US9909114B2
(en)
|
2013-03-28 |
2018-03-06 |
Infectious Disease Research Institute |
Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
|
BR112015025709A2
(pt)
|
2013-04-18 |
2017-07-18 |
Immune Design Corp |
monoterapia com gla para uso em tratamento de câncer
|
EP2994162B1
(en)
*
|
2013-05-08 |
2021-04-07 |
Pharmgate Biologics Inc. |
Vaccine for pcv2 and mycoplasma
|
WO2015132619A1
(en)
|
2013-05-15 |
2015-09-11 |
The Governors Of The University Of Alberta |
E1e2 hcv vaccines and methods of use
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
GB201310008D0
(en)
|
2013-06-05 |
2013-07-17 |
Glaxosmithkline Biolog Sa |
Immunogenic composition for use in therapy
|
AU2014302282B2
(en)
|
2013-06-26 |
2018-09-13 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for dengue virus vaccines
|
EP3016968B1
(en)
|
2013-07-01 |
2019-06-26 |
Newsouth Innovations Pty Limited |
Diagnosis and treatment of autoimmune diseases
|
US9975925B2
(en)
|
2013-08-28 |
2018-05-22 |
Glaxosmithkline Biologicals S.A. |
Influenza antigens and antibodies
|
CN104436157A
(zh)
|
2013-09-23 |
2015-03-25 |
恩金生物有限公司 |
流感疫苗和治疗
|
EP3063171B1
(en)
|
2013-11-01 |
2019-07-24 |
University Of Oslo |
Albumin variants and uses thereof
|
EP3068426B1
(en)
|
2013-11-13 |
2020-02-12 |
University Of Oslo |
Outer membrane vesicles and uses thereof
|
DK3069138T3
(en)
|
2013-11-15 |
2019-04-08 |
Univ Oslo Hf |
CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF
|
WO2015077442A2
(en)
|
2013-11-20 |
2015-05-28 |
La Jolla Institute For Allergy And Immunology |
Grass pollen immunogens and methods and uses for immune response modulation
|
EP3071228A2
(en)
|
2013-11-20 |
2016-09-28 |
La Jolla Institute for Allergy and Immunology |
Pan pollen immunogens and methods and uses thereof for immune response modulation
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
EP3915579A1
(en)
|
2013-12-31 |
2021-12-01 |
Infectious Disease Research Institute |
Single vial vaccine formulations
|
WO2015103104A1
(en)
|
2014-01-06 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Attenuated salmonella enterica
|
NZ760783A
(en)
|
2014-01-21 |
2023-07-28 |
Pfizer |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2015112485A1
(en)
|
2014-01-21 |
2015-07-30 |
Immune Design Corp. |
Compositions for use in the treatment of allergic conditions
|
EP3104877B1
(en)
|
2014-02-11 |
2020-01-22 |
The USA, as represented by The Secretary, Department of Health and Human Services |
Pcsk9 vaccine and methods of using the same
|
TW201620927A
(zh)
|
2014-02-24 |
2016-06-16 |
葛蘭素史密斯克藍生物品公司 |
Uspa2蛋白質構築體及其用途
|
WO2015131053A1
(en)
|
2014-02-28 |
2015-09-03 |
Alk-Abelló A/S |
Polypeptides derived from phl p and methods and uses thereof for immune response modulation
|
AU2015242154B2
(en)
|
2014-04-03 |
2019-04-04 |
Biondvax Pharmaceuticals Ltd. |
Compositions of multimeric-multiepitope influenza polypeptides and their production
|
CN115925946A
(zh)
|
2014-05-28 |
2023-04-07 |
阿吉纳斯公司 |
抗gitr抗体和其使用方法
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
JP6820830B2
(ja)
|
2014-07-18 |
2021-01-27 |
ユニヴァーシティ オブ ワシントン |
がんワクチン組成物およびその使用方法
|
WO2016012385A1
(en)
|
2014-07-21 |
2016-01-28 |
Sanofi Pasteur |
Vaccine composition comprising ipv and cyclodextrins
|
NZ766003A
(en)
|
2014-07-23 |
2024-01-26 |
Children’S Hospital & Res Center At Oakland |
Factor h binding protein variants and methods of use thereof
|
ES2924988T3
(es)
|
2014-10-10 |
2022-10-13 |
Univ Michigan Regents |
Composiciones con nanoemulsiones para prevenir, inhibir o eliminar una enfermedad alérgica e inflamatoria
|
BR112017008952A2
(pt)
|
2014-11-02 |
2018-01-16 |
Univ North Carolina Chapel Hill |
métodos e composições para vírus recombinantes da dengue para desenvolvimento de vacina e diagnóstico
|
MA40920A
(fr)
|
2014-11-07 |
2017-09-12 |
Takeda Vaccines Inc |
Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
|
AU2015252119A1
(en)
|
2014-11-07 |
2016-05-26 |
Takeda Vaccines, Inc. |
Hand, foot, and mouth vaccines and methods of manufacture and use thereof
|
BE1023004A1
(fr)
|
2014-12-10 |
2016-10-31 |
Glaxosmithkline Biologicals Sa |
Procede de traitement
|
WO2016109880A1
(en)
|
2015-01-06 |
2016-07-14 |
Immunovaccine Technologies Inc. |
Lipid a mimics, methods of preparation, and uses thereof
|
IL252915B2
(en)
|
2015-01-15 |
2024-04-01 |
Pfizer |
Immunogenic preparations for use in pneumococcal vaccines
|
US10596247B2
(en)
|
2015-02-20 |
2020-03-24 |
Board Of Regents, The University Of Texas System |
Methods and compositions for attenuated chlamydia as vaccine and vector
|
EP3268034A4
(en)
|
2015-03-05 |
2018-11-14 |
Northwestern University |
Non-neuroinvasive viruses and uses thereof
|
JP2018511655A
(ja)
|
2015-03-20 |
2018-04-26 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物
|
BR112017020178A2
(pt)
|
2015-03-26 |
2018-06-12 |
Gpn Vaccines Pty Ltd |
vacina estreptocócica
|
CA2986961C
(en)
|
2015-05-26 |
2023-07-25 |
Ohio State Innovation Foundation |
Nanoparticle based vaccine strategy against swine influenza virus
|
EP3302536A1
(en)
|
2015-06-03 |
2018-04-11 |
Affiris AG |
Il-23-p19 vaccines
|
JP2018524323A
(ja)
|
2015-06-26 |
2018-08-30 |
セキラス ユーケー リミテッド |
抗原がマッチしたインフルエンザワクチン
|
CN107849119A
(zh)
|
2015-07-07 |
2018-03-27 |
阿费里斯股份公司 |
用于治疗和预防IgE介导的疾病的疫苗
|
AU2016295566B2
(en)
|
2015-07-21 |
2019-06-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
CN107949573B
(zh)
|
2015-09-01 |
2022-05-03 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
ES2607715B1
(es)
|
2015-10-01 |
2018-01-17 |
Solutex Na, Lcc |
Proceso para la preparación y estabilización de emulsiones con omega-3 mediante redes cristalinas isométricas de derivados de celulosa
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB201518668D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Immunogenic Comosition
|
EP3377098A1
(en)
|
2015-11-20 |
2018-09-26 |
Pfizer Inc |
Immunogenic compositions for use in pneumococcal vaccines
|
CA3007233A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Antibodies and methods of use thereof
|
WO2017109698A1
(en)
|
2015-12-22 |
2017-06-29 |
Glaxosmithkline Biologicals Sa |
Immunogenic formulation
|
SG11201805621SA
(en)
|
2016-01-19 |
2018-08-30 |
Pfizer |
Cancer vaccines
|
GB201603625D0
(en)
|
2016-03-02 |
2016-04-13 |
Glaxosmithkline Biolog Sa |
Novel influenza antigens
|
MX2018010961A
(es)
|
2016-03-10 |
2019-03-28 |
Aperisys Inc |
Proteínas de fusión de unión a antígeno con dominios de proteína de choque térmico de 70 kilodaltons (hsp70) modificada.
|
WO2017158421A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Anti-viral engineered immunoglobulins
|
US11319383B2
(en)
|
2016-03-14 |
2022-05-03 |
Universitetet | Oslo |
Engineered immunoglobulins with altered FcRn binding
|
WO2017167768A1
(en)
|
2016-03-28 |
2017-10-05 |
Glaxosmithkline Biologicals S.A. |
Novel vaccine composition
|
RU2761870C2
(ru)
|
2016-05-16 |
2021-12-13 |
Инфекшес Дизис Рисёрч Инститьют |
Состав, содержащий агонист tlr, и способы применения
|
US11173207B2
(en)
|
2016-05-19 |
2021-11-16 |
The Regents Of The University Of Michigan |
Adjuvant compositions
|
KR20190009308A
(ko)
|
2016-05-21 |
2019-01-28 |
인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) |
2차 결핵 및 비결핵성 마이코박테리아 감염을 치료하기 위한 조성물 및 방법
|
NZ749355A
(en)
|
2016-05-27 |
2023-04-28 |
Agenus Inc |
Anti-tim-3 antibodies and methods of use thereof
|
EP3463300A1
(en)
|
2016-06-01 |
2019-04-10 |
Infectious Disease Research Institute |
Nanoalum particles containing a sizing agent
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
EP3471761A2
(en)
|
2016-06-21 |
2019-04-24 |
University Of Oslo |
Hla binding vaccine moieties and uses thereof
|
MX2019002178A
(es)
|
2016-08-23 |
2019-09-18 |
Glaxosmithkline Biologicals Sa |
Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
|
GB201614799D0
(en)
|
2016-09-01 |
2016-10-19 |
Glaxosmithkline Biologicals Sa |
Compositions
|
US11801290B2
(en)
|
2016-09-16 |
2023-10-31 |
Access To Advanced Health Institute |
Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
|
WO2018060288A1
(en)
|
2016-09-29 |
2018-04-05 |
Glaxosmithkline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
CN117586403A
(zh)
|
2016-10-11 |
2024-02-23 |
艾吉纳斯公司 |
抗lag-3抗体及其使用方法
|
WO2018096396A1
(en)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Albumin variants and uses thereof
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
KR20190103226A
(ko)
|
2017-01-13 |
2019-09-04 |
아게누스 인코포레이티드 |
Ny-eso-1에 결합하는 t 세포 수용체 및 이의 사용 방법
|
BR112019014833A2
(pt)
|
2017-01-20 |
2020-04-14 |
Pfizer |
composições imunogênicas para uso em vacinas pneumococais
|
US11254712B2
(en)
|
2017-03-30 |
2022-02-22 |
The University Of Queensland |
Chimeric molecules and uses thereof
|
CN110662557A
(zh)
|
2017-03-31 |
2020-01-07 |
葛兰素史克知识产权开发有限公司 |
免疫原性组合物、用途和治疗方法
|
WO2018178265A1
(en)
|
2017-03-31 |
2018-10-04 |
Glaxosmithkline Intellectual Property Development Limited |
Immunogenic composition, use and method of treatment
|
CA3059366A1
(en)
|
2017-04-13 |
2018-10-18 |
Agenus Inc. |
Anti-cd137 antibodies and methods of use thereof
|
MA50957A
(fr)
|
2017-05-01 |
2020-10-14 |
Agenus Inc |
Anticorps anti-tigit et leurs méthodes d'utilisation
|
AU2018283973A1
(en)
|
2017-06-11 |
2020-01-16 |
Molecular Express, Inc. |
Methods and compositions for substance use disorder vaccine formulations and uses thereof
|
CN111315362A
(zh)
|
2017-06-15 |
2020-06-19 |
传染病研究所 |
纳米结构脂质载剂和稳定乳剂以及其用途
|
JP2020527579A
(ja)
|
2017-07-18 |
2020-09-10 |
イン3バイオ・リミテッドIn3Bio Ltd. |
合成タンパク質およびその治療学的用途
|
CN110996994A
(zh)
|
2017-08-14 |
2020-04-10 |
葛兰素史密丝克莱恩生物有限公司 |
加强免疫应答的方法
|
US11123415B2
(en)
|
2017-08-16 |
2021-09-21 |
Ohio State Innovation Foundation |
Nanoparticle compositions for Salmonella vaccines
|
WO2019046856A1
(en)
|
2017-09-04 |
2019-03-07 |
Agenus Inc. |
T-CELL RECEPTORS THAT BIND TO SPECIFIC PHOSPHOPEPTIDES OF MIXED LINEAR LEUKEMIA (MLL) AND METHODS OF USE THEREOF
|
WO2019048928A1
(en)
|
2017-09-07 |
2019-03-14 |
University Of Oslo |
VACCINE MOLECULES
|
US20210069319A1
(en)
|
2017-09-07 |
2021-03-11 |
University Of Oslo |
Vaccine molecules
|
AU2018330165A1
(en)
|
2017-09-08 |
2020-04-02 |
Access To Advanced Health Institute |
Liposomal formulations comprising saponin and methods of use
|
US11566050B2
(en)
|
2017-10-18 |
2023-01-31 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for norovirus vaccines and diagnostics
|
CN111615397A
(zh)
|
2017-11-03 |
2020-09-01 |
武田疫苗股份有限公司 |
寨卡疫苗和免疫原性组合物及其使用方法
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
GB201721576D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
Hla antigens and glycoconjugates thereof
|
GB201721582D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
S aureus antigens and immunogenic compositions
|
US11633471B2
(en)
|
2018-03-06 |
2023-04-25 |
Unm Rainforest Innovations |
Compositions and methods for reducing serum triglycerides
|
BR112020024285A2
(pt)
|
2018-06-12 |
2021-03-02 |
Glaxosmithkline Biologicals S.A. |
polinucleotídeos e polipeptídeos de adenovírus
|
MX2021001479A
(es)
|
2018-08-07 |
2021-04-28 |
Glaxosmithkline Biologicals Sa |
Novedosos procesos y vacunas.
|
JP2021534761A
(ja)
|
2018-08-23 |
2021-12-16 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性タンパク質および組成物
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
WO2020044267A1
(en)
|
2018-08-29 |
2020-03-05 |
Centre Hospitalier Universitaire Vaudois |
Ebola vaccine compositions and methods of using same
|
CN111315407B
(zh)
|
2018-09-11 |
2023-05-02 |
上海市公共卫生临床中心 |
一种广谱抗流感疫苗免疫原及其应用
|
EP3890775A1
(en)
|
2018-12-06 |
2021-10-13 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic compositions
|
EP3894431A2
(en)
|
2018-12-12 |
2021-10-20 |
GlaxoSmithKline Biologicals SA |
Modified carrier proteins for o-linked glycosylation
|
US20220016229A1
(en)
|
2018-12-12 |
2022-01-20 |
Pfizer Inc. |
Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
|
WO2020128012A1
(en)
|
2018-12-21 |
2020-06-25 |
Glaxosmithkline Biologicals Sa |
Methods of inducing an immune response
|
GB201901608D0
(en)
|
2019-02-06 |
2019-03-27 |
Vib Vzw |
Vaccine adjuvant conjugates
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
CN113573730A
(zh)
|
2019-03-05 |
2021-10-29 |
葛兰素史密斯克莱生物公司 |
乙型肝炎免疫方案和组合物
|
CA3136278A1
(en)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
EP3956666A1
(en)
|
2019-04-18 |
2022-02-23 |
GlaxoSmithKline Biologicals S.A. |
Antigen binding proteins and assays
|
MX2021014363A
(es)
|
2019-05-25 |
2022-02-21 |
Infectious Disease Res Inst |
Composicion y metodo para secar por pulverizacion una emulsion de vacuna adyuvante.
|
JP2022539067A
(ja)
|
2019-06-25 |
2022-09-07 |
イン3バイオ・リミテッド |
安定化キメラ合成タンパク質及びその治療的使用
|
CA3146900A1
(en)
|
2019-07-21 |
2021-01-28 |
Glaxosmithkline Biologicals Sa |
Therapeutic viral vaccine
|
EP3770269A1
(en)
|
2019-07-23 |
2021-01-27 |
GlaxoSmithKline Biologicals S.A. |
Quantification of bioconjugate glycosylation
|
MX2022001488A
(es)
|
2019-08-05 |
2022-03-02 |
Glaxosmithkline Biologicals Sa |
Composicion inmunogenica.
|
MX2022002315A
(es)
|
2019-08-30 |
2022-03-25 |
Agenus Inc |
Anticuerpos anti-cd96 y sus metodos de uso.
|
EP3799884A1
(en)
|
2019-10-01 |
2021-04-07 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic compositions
|
EP3808765A1
(en)
|
2019-10-14 |
2021-04-21 |
ETH Zurich |
Cell line for tcr discovery and engineering and methods of use thereof
|
EP4051696A1
(en)
|
2019-11-01 |
2022-09-07 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
EP4058581A1
(en)
|
2019-11-15 |
2022-09-21 |
Infectious Disease Research Institute |
Rig-i agonist and adjuvant formulation for tumor treatment
|
NL2030835B1
(en)
|
2020-01-24 |
2022-12-29 |
Aim Immunotech Inc |
Methods, compositions, and vaccinces for treating a virus infection
|
WO2021160887A1
(en)
|
2020-02-14 |
2021-08-19 |
Immunor As |
Corona virus vaccine
|
US20230085173A1
(en)
|
2020-02-21 |
2023-03-16 |
Pfizer Inc. |
Purification of saccharides
|
EP4107170A2
(en)
|
2020-02-23 |
2022-12-28 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
AU2021252164A1
(en)
|
2020-04-09 |
2022-12-15 |
Finncure Oy |
Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
|
US20230234992A1
(en)
|
2020-06-05 |
2023-07-27 |
Glaxosmithkline Biologicals Sa |
Modified betacoronavirus spike proteins
|
EP4171629A1
(en)
|
2020-06-29 |
2023-05-03 |
GlaxoSmithKline Biologicals S.A. |
Adjuvants
|
US20240010726A1
(en)
|
2020-08-17 |
2024-01-11 |
Universität Basel |
Lfa-1 signalling mediator for use in cancer therapy
|
BR112023002804A2
(pt)
|
2020-08-24 |
2023-03-14 |
Sanofi Pasteur Inc |
Vacinas para covid-19 com adjuvantes em emulsão de esqualeno contendo tocoferol
|
US11225508B1
(en)
|
2020-09-23 |
2022-01-18 |
The University Of North Carolina At Chapel Hill |
Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
|
WO2022083760A1
(zh)
|
2020-10-23 |
2022-04-28 |
江苏省疾病预防控制中心(江苏省公共卫生研究院) |
融合蛋白及其应用
|
CA3199610A1
(en)
|
2020-10-27 |
2022-05-05 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
WO2022097010A1
(en)
|
2020-11-04 |
2022-05-12 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
JP2023549736A
(ja)
|
2020-11-10 |
2023-11-29 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
WO2022152939A1
(en)
|
2021-01-18 |
2022-07-21 |
Conserv Bioscience Limited |
Coronavirus immunogenic compositions, methods and uses thereof
|
EP4032547A1
(en)
|
2021-01-20 |
2022-07-27 |
GlaxoSmithKline Biologicals S.A. |
Hsv1 fce derived fragements for the treatment of hsv
|
MX2023009728A
(es)
|
2021-02-19 |
2023-08-30 |
Sanofi Pasteur Inc |
Vacuna recombinante meningococica b.
|
WO2022175423A1
(en)
|
2021-02-22 |
2022-08-25 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition, use and methods
|
WO2022200582A1
(en)
|
2021-03-26 |
2022-09-29 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
CA3221074A1
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
TW202306969A
(zh)
|
2021-05-28 |
2023-02-16 |
美商輝瑞大藥廠 |
包含結合之莢膜醣抗原的免疫原組合物及其用途
|
CA3222568A1
(en)
|
2021-06-28 |
2023-01-05 |
Glaxosmithkline Biologicals Sa |
Novel influenza antigens
|
WO2023020993A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
WO2023020992A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
WO2023020994A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
WO2023061993A1
(en)
|
2021-10-13 |
2023-04-20 |
Glaxosmithkline Biologicals Sa |
Polypeptides
|
CA3237496A1
(en)
|
2021-11-18 |
2023-05-25 |
Matrivax, Inc. |
Immunogenic fusion protein compositions and methods of use thereof
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|